Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis

X C Xu1, N Sneige, X Liu

  • 1Department of Clinical Cancer Prevention, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

Cancer Research
|November 26, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2.

Annals of oncology : official journal of the European Society for Medical Oncology·2014
Same author

Training two-layered feedforward networks with variable projection method.

IEEE transactions on neural networks·2008
Same author

Does propofol and alfentanil-induced sedation cause periodic apnoea in chronic renal failure patients?

International journal of clinical practice·2007
Same author

Evaluation of the Cobra perilaryngeal airway (CPLA) as an airway conduit.

European journal of anaesthesiology·2007
Same author

Interaction index and different methods for determining drug interaction in combination therapy.

Journal of biopharmaceutical statistics·2007
Same journal

CDK2 Inhibition Exerts RB-Independent Antitumor Activity in CDK4/6 Inhibitor-Resistant HR+/HER2- Breast Cancer.

Cancer research·2026
Same journal

A Clinically Integrated Pediatric Patient-Derived Xenograft Program Enables Evaluation of Cohort and Patient-Specific Biology and Therapeutic Strategies.

Cancer research·2026
Same journal

Editor's Note: Heterodimerization of Insulin-like Growth Factor Receptor/Epidermal Growth Factor Receptor and Induction of Survivin Expression Counteract the Antitumor Action of Erlotinib.

Cancer research·2026
Same journal

Editor's Note: Deguelin Analogue SH-1242 Inhibits Hsp90 Activity and Exerts Potent Anticancer Efficacy with Limited Neurotoxicity.

Cancer research·2026
Same journal

Retraction: Two Functional Epitopes of Pigment Epithelial-Derived Factor Block Angiogenesis and Induce Differentiation in Prostate Cancer.

Cancer research·2026
Same journal

Editor's Note: Chronic Stress Facilitates Lung Tumorigenesis by Promoting Exocytosis of IGF2 in Lung Epithelial Cells.

Cancer research·2026
See all related articles

Decreased expression of retinoic acid receptor-beta (RAR-beta) is linked to breast cancer development. This reduction occurs in ductal carcinoma in situ and invasive breast cancer, independent of estrogen receptor status.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Retinoic acid receptors (RARs) and retinoid X receptors (RXRs) are crucial for regulating cell growth, differentiation, and apoptosis.
  • These nuclear receptors are implicated in preventing breast carcinogenesis.
  • Understanding their expression patterns in breast cancer is vital for therapeutic strategies.

Purpose of the Study:

  • To investigate the expression levels of RARs (alpha, beta, gamma) and RXR-alpha in normal and cancerous breast tissues.
  • To determine the correlation between RAR-beta expression and breast cancer progression and differentiation.
  • To assess the relationship between RAR-beta expression and estrogen receptor status in breast cancer.

Main Methods:

  • Analysis of mRNA expression for RARs and RXR-alpha using in situ hybridization.

Related Experiment Videos

  • Study included histological sections from 70 breast cancer patients: adjacent normal tissue, ductal carcinoma in situ, and invasive cancer.
  • Quantification of receptor expression in different tissue types and cancer grades.

    • Main Results:

    • High expression of RARs (alpha, beta, gamma) and RXR-alpha was observed in adjacent normal breast tissues.
    • A significant decrease in RAR-beta expression was found in ductal carcinoma in situ (83.1%) and invasive carcinomas (51.6%).
    • Poorly differentiated invasive carcinomas showed particularly low RAR-beta expression (35.7%).
    • No correlation was found between RAR-beta expression and estrogen receptor status.

    Conclusions:

    • Reduced RAR-beta expression is implicated in the development of breast cancer.
    • The downregulation of RAR-beta appears to be an early event in breast carcinogenesis.
    • RAR-beta expression changes in breast cancer are independent of estrogen receptor status, suggesting distinct regulatory pathways.